Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)
Retrospective analysis shows infection risk factors and bacterial infections in patients post CAR-T therapy, suggesting enhanced management strategies may be needed.
Key Points
Severe infections frequently occur in patients undergoing chimeric antigen receptor T-cell therapy, highlighting critical infection-related mortality.
Of 933 total infections documented, 76.7% were within the first three months and 0.163 infections per patient were recorded from days 1 to 10.
Assessment using the French DESCAR-T registry highlighted various types of infections including bacterial, viral, and parasitic, with significant risk factors identified.
Findings suggest a need for enhanced monitoring and management strategies for infection risks in CAR-T therapy patients; external validation warranted.